Emergent inks $225M cash smallpox deal as Chimerix implodes on reorg, FDA trouble
Emergent BioSolutions has made a name for itself ever since the late 1990s by making drugs that are needed by the US government. Monday, it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
